LakeShore Biopharma Co., Ltd: current liabilities
Current liabilities for LakeShore Biopharma Co., Ltd. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All LakeShore Biopharma Co., Ltd financial histories
What this measure means
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
Exact concept: us-gaap:LiabilitiesCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2022-03-31 to 2025-03-31. The SEC response was captured on 2026-09-21.
Coverage by original unit
- CNY: 2022-03-31 to 2025-03-31.
- USD: 2023-03-31 to 2025-03-31.
These are separate reported series. A newer period in one unit does not update another unit’s history or establish a currency conversion.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-03-31 | 824,752,522 | CNY | 2025-07-31 | 20-F · 0001213900-25-069880 |
| At date | 2024-03-31 | 802,225,732 | CNY | 2025-07-31 | 20-F · 0001213900-25-069880 |
| At date | 2023-03-31 | 658,761,944 | CNY | 2024-08-15 | 20-F · 0001213900-24-069344 |
| At date | 2022-03-31 | 475,914,160 | CNY | 2023-07-26 | 20-F · 0001213900-23-060012 |
| At date | 2025-03-31 | 114,896,843 | USD | 2025-07-31 | 20-F · 0001213900-25-069880 |
| At date | 2024-03-31 | 113,069,168 | USD | 2024-08-15 | 20-F · 0001213900-24-069344 |
| At date | 2023-03-31 | 95,865,936 | USD | 2023-07-26 | 20-F · 0001213900-23-060012 |
Related financial histories
- LakeShore Biopharma Co., Ltd: total assets
- LakeShore Biopharma Co., Ltd: total liabilities
- LakeShore Biopharma Co., Ltd: stockholders equity
- LakeShore Biopharma Co., Ltd: net income or loss
- LakeShore Biopharma Co., Ltd: operating cash flow
- LakeShore Biopharma Co., Ltd: capital expenditure payments
- LakeShore Biopharma Co., Ltd: revenue
- LakeShore Biopharma Co., Ltd: financing cash flow
- LakeShore Biopharma Co., Ltd: investing cash flow
- LakeShore Biopharma Co., Ltd: retained earnings or deficit
- LakeShore Biopharma Co., Ltd: basic weighted-average shares
- LakeShore Biopharma Co., Ltd: diluted weighted-average shares
- LakeShore Biopharma Co., Ltd: basic earnings per share
- LakeShore Biopharma Co., Ltd: diluted earnings per share
- LakeShore Biopharma Co., Ltd: income tax expense or benefit
- LakeShore Biopharma Co., Ltd: net property, plant and equipment
- LakeShore Biopharma Co., Ltd: share-based compensation expense
- LakeShore Biopharma Co., Ltd: operating income or loss
- LakeShore Biopharma Co., Ltd: current assets
- LakeShore Biopharma Co., Ltd: current accounts payable
- LakeShore Biopharma Co., Ltd: net finite-lived intangible assets
- LakeShore Biopharma Co., Ltd: net current accounts receivable
- LakeShore Biopharma Co., Ltd: operating expenses
- LakeShore Biopharma Co., Ltd: net inventory
- LakeShore Biopharma Co., Ltd: gross profit
- LakeShore Biopharma Co., Ltd: cost of revenue
- LakeShore Biopharma Co., Ltd: research and development expense
Inspect the source
- Entity
- LakeShore Biopharma Co., Ltd / CIK 0001946399
- Captured
- 2026-09-21T17:37:41.722Z
- SEC response SHA-256
4732e86fe3d6cf1119c0187b0320d5a7aad6429e9d3dd754cbf153575c5b45e8
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001946399.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))